Lenvatinib and pembrolizumab with or without BCAA for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing whether adding a special amino acid supplement (BCAA) to a combination of two drugs (lenvatinib and pembrolizumab) can help treat liver cancer that cannot be removed by surgery. It may be a good option if you have not had similar treatments before and your liver function is still fairly good.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 74 years old.
- You have been diagnosed with a type of liver cancer called hepatocellular carcinoma (HCC) that cannot be removed by surgery.
- You have not had any prior targeted therapy or immunotherapy for your cancer.
- Your liver function is still good (Child-Pugh class A), meaning it works well enough.
- You have not had a major bleeding episode in your stomach or esophagus in the last 6 months, and you do not have untreated varicose veins in your esophagus.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
This trial studies whether combining pembrolizumab and lenvatinib with a focused radiation treatment (SBRT) can improve outcomes for people with liver cancer that has a tumor blood-clot in the portal vein. It may help shrink the cancer and control it locally while also supporting the immune system to fight cancer.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.